Skip to main content

Table 3 Levels of LecT-Hepa, FIB-4 and APRI in45 CHC patients during 48 weeks course of IFN therapy

From: LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients

Weeks 0 4 12 24 48
LecT-Hepa      
 Non-LC (n = 18) −9.22 ± 3.77 −9.09 ± 4.66 −8.72 ± 5.66 −8.71 ± 4.69 −8.98 ± 4.88
 Indeterminate (n = 14) −2.10 ± 4.63 −2.14 ± 5.02 −2.12 ± 4.72 −3.47 ± 5.13 −4.40 ± 5.01
 LC (n = 13) 0.83 ± 5.06 2.82 ± 5.60 2.38 ± 5.32 1.29 ± 4.39 −0.17
 Total (n = 45) −4.69 ± 6.11 −3.25 ± 7.01 −3.24 ± 6.97 −4.19 ± 6.21 −7.31 ± 5.35
FIB-4      
 Non-LC (n = 18) 1.63 ± 1.06 1.72 ± 0.70 2.03 ± 0.94 1.87 ± 1.03 1.81 ± 0.68
 Indeterminate (n = 14) 4.17 ± 3.11 2.79 ± 2.17 3.33 ± 2.49 2.91 ± 1.61 2.84 ± 0.91
 LC (n = 13) 4.57 ± 2.71 3.80 ± 1.95 4.35 ± 1.91 3.94 ± 1.53 4.55
 Total (n = 45) 3.27 ± 2.68 2.70 ± 1.85 3.15 ± 2.04 2.79 ± 1.60 2.22 ± 1.01
APRI      
 Non-LC (n = 18) 0.96 ± 1.11 0.54 ± 0.27 0.58 ± 0.36 0.51 ± 0.29 0.66 ± 0.76
 Indeterminate (n = 14) 2.44 ± 2.18 0.70 ± 0.32 0.76 ± 0.37 0.82 ± 0.56 0.89 ± 0.48
 LC (n = 13) 2.92 ± 3.15 1.26 ± 0.61 1.19 ± 0.45 1.10 ± 0.46 1.44
 Total (n = 45) 1.98 ± 2.31 0.81 ± 0.52 0.83 ± 0.46 0.78 ± 0.49 0.76 ± 0.69